The rate of high p53 positivity (>60% p53 positive tumor cells; clinical score 3) also followed this trend, being 17.2% (26/151) in TT patients, 12.9% (19/147) in TG patients, and 5.7% (3/53) in GG patients (Table 4). This evidence concerns the gene TP53 and neoplasm.